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The objective of this special issue is to present current ﬁnd-
ings on how PPARs can tilt the delicate balance between
host defense and parasite survival to aﬀect the outcome of
parasitic infections. The volumecontainsﬁve comprehensive
reviews and one original research article that describe the
mechanisms of action of PPARs on several parasitic diseases
which infect diﬀerently. The pathogens include the malaria
parasite Plasmodium falciparum which invades hepatocytes
anderythrocytes,theLeishmania specieswhichinfectmacro-
phages, the intracellular protozoan Trypanosoma cruziwhich
invades all tissues, and the helminth Schistosoma species,
which live in extracellular environment of speciﬁc organs.
Whereas it is well known that many parasitic diseases are
exacerbated by the activation of T helper 2, recent research
ontheanti-inﬂammatory alternativelyactivated macrophage
(AAM), which is activated by PPARγ, shows that there is
another facet to the host immune response [1]. PPARγ
primes the diﬀerentiation of macrophages towards AAM
rather than the proinﬂammatory classically activated macro-
phage (CAM) phenotype, by promoting arginase while
suppressing inducible nitric oxide synthase expression. This
activity favors the survival of pathogens, which may be sus-
ceptible to the free radical nitric oxide. On the other hand,
PPARγ activation becomes beneﬁcial to the host in malaria.
This special issue presents studies that, timely, characterize
the interaction between parasites and these macrophages
which express the PPAR nuclear factors.
Malaria is the most devastating among diseases of par-
asitic protozoa. L. Serghides explains how PPAR agonists
relieve immunopathology in cerebral malaria. PPARγ-me-
diated transcription of CD36, a scavenger receptor which
enhances phagocytosis and facilitates the removal of para-
sitized erythrocytes, leads to reduced parasitemia. In addi-
tion, the anti-inﬂammatory action of PPARγ protects the
central nervous system from inﬂammation-mediated de-
struction. Y. Ren concurs that the strategy to augment the
upregulation of CD36 is potentially therapeutic. Using
PPARγ agonist rosiglitazone as adjunctive therapy during
treatment of cerebral malaria has successfully gone through
phase I/IIa trial in Thailand and now awaits a ﬁnal random-
ized double-blind placebo-controlled clinical trial.
On the contrary, PPAR activation may beneﬁt the par-
asite in other infections. For protozoan parasites, trypan-
osomatids set as examples. M. Chan et al. describe how
the activation of PPARα and PPARγ by cutaneous and vis-
ceral Leishmania species may promote their survival within
macrophages. E. Hovsepian et al. also discuss how Try-
panosoma cruzi-mediated PPAR activation inﬂuences intra-
cellularparasite survival. Formetazoan parasites, B.Anthony
et al. review how the Schistosoma species activate PPARα,
PPARγ, and AAM to potentiate survival.
The PPARγ agonist rosiglitazone has been shown to pos-
sess anti-inﬂammatory, neuroprotective and neuroregenera-
tive properties. However, although rosiglitazone (drug name
Avandia, from GlaxoSmithKline) is still being used to treat
type 2 diabetes in the United States, the drug is withdrawn
in Europe because of adverse eﬀects, especially to the heart.
Pioglitazone may be a better alternative. Extending from
rosiglitazone and PPARγ, K. Chen et al. report the protective
activity of Wy14643, an agonist of PPARα, the isoform pre-
valent in the liver, towards hypoxia reoxygenation injury in
rodent hepatocytes.2 PPAR Research
Many parasitic diseases are widespread in developing
countries. Historically,theyhavebeenregarded as“neglected
tropicaldiseases”[2].Withparasiticinfectionsbeingincreas-
ingly diagnosed in developed countries due to global travel
and immigration, their control is being pursued by many
investigators [3,4].Publicandprivateagencies,suchas TDR,
Special Programme for Research and Training in Tropical
Diseases of World Health Organization, and Bill & Melinda
Gates Foundation, using arrangements such as public-
private partnerships, are determined to target such diseases
of poverty. Scientists from many countries are actively re-
searching various aspects of parasitic diseases. With this
background, we sincerely thank the international cast of
scientists who have contributed to this special issue on
PPARs and parasites. They come from diﬀerent countries:
Argentina, Australia, Canada, China, United Kingdom, and
United States, covering the continents Australia, Europe,
North, and South America.
In summary, this special issue provides a glimpse of our
contemporary understanding on PPAR involvement in para-
sitic diseases. Diﬀerent angles have been explored, for exam-
ple, while PPAR agonists may decrease immunopathology
of cerebral malaria, they may enhance parasite survival in
leishmaniasis. We hope the readers will ﬁnd this special issue
of PPAR Research informative and will be inspired to make
their own contributions to the challenge our world faces
from the diverse parasitic infections.
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